Experimental Models for Aging and their Potential for Novel Drug Discovery

Area of Science:

• Gerontology and pharmacology of aging.
• Preclinical research models for drug discovery.

Background:

• Developing antiaging drugs requires understanding suitable preclinical models.
• This review focuses on invertebrate and vertebrate models for evaluating antiaging compounds.

Purpose of the Study:

• To review invertebrate and vertebrate preclinical models for antiaging drug efficacy.
• To identify models for extending lifespan and healthspan.

Main Methods:

• Literature review of aging research, antiaging drugs, and experimental aging models.
• Discussion of key preclinical models used in aging pharmacology and lifespan extension research.

Main Results:

• Dietary restriction (DR) extends lifespan across organisms; DR mimetics like resveratrol, rapamycin, and metformin are discussed.
• Key drug targets include sirtuins, IGF-1, and mTOR, all modulated by DR.
• Invertebrate models are primary for drug screening; Heterogeneous mouse models (HET) and P8 mice are suitable rodent models.

Conclusions:

• Molecular biology reveals aging pathways. Invertebrate models excel in drug screening.
• The Heterogeneous mouse model (HET) is optimal for preclinical antiaging drug studies.
• Non-human primates are crucial for preclinical evaluation due to human similarity; further research is needed for human quality of life.